This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

In this interview, rare disease expert Oxana Iliach discusses challenges with rare disease drug development and how they can ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-T) from The Globe and Mail including charting and trades.

Zai Lab Limited today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company's potential first-in-class and best-in-class, ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

The U.S. Food and Drug Administration (FDA) has unveiled a strategic ... NAMs streamline the preclinical phase of drug development. Studies for monoclonal antibodies, which typically require ...

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (”Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, CEO of Aspire, ...